Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2005

View Archived Issues

Medivir reflects on Q3 developments

Targeting mGluR1 for epilepsy

USP7: new target for cancer with inhibitors identified at Hybrigenics

Bioreductive prodrugs facilitate selective targeting of hypoxic tumor regions

Novel tumor-localizing agents described

R-112 disappoints in phase II comparative study in allergic rhinitis

Bausch & Lomb and PTC Therapeutics collaborate in ophthalmology

ArQule seeks to begin phase I studies with ARQ-197

Wyeth awarded new contract for development of therapeutic HIV vaccines

Alza modifies U.S. clinical development program for OROS Hydromorphone

Second approvable letter for diquafosol tetrasodium ophthalmic solution

New phase I study investigates INNO-105 in advanced solid malignancies

Private equity financing to support NeurogesX' development of Transacin

Bausch & Lomb licenses compounds from Cephalon for ophthalmic use

Provectus studies PV-10 for breast cancer in phase I trial

ACP-103 reduces haloperidol-induced akathisia in patients with schizophrenia

Phase I data on chemotherapeutic RH1 presented

S-18407, a novel alpha4beta1 integrin inhibitor, effective in murine Lyme arthritis

Opticin found to induce antiangiogenic effects in vitro and in vivo

New cancer vaccine activates host immune response

New agents described for treating cardiovascular disorders

Novel compounds with potential for inflammatory disorders imparted in patents

Recent patents report new treatments for thrombotic disorders

Preclinical studies reveal activity of BMS-354825 in various cancer types

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...